Current prophylactic strategies against hepatitis B virus recurrence after liver transplantation

作     者：Li Jiang Li-Sheng Jiang Nan-Sheng Cheng Lu-Nan Yan 

作者机构：Department of Liver and Vascular Surgery Liver Transplantation Center West China Hospital of Sichuan University Chengdu 610041 Sichuan Province China Department ofBiliary Surgery West China Hospital of Sichuan University Chengdu 610041 Sichuan Province China 

出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)

年 卷 期：2009年第15卷第20期

页      面：2489-2499页

核心收录：

学科分类：090603[农学-临床兽医学] 0710[理学-生物学] 07[理学] 08[工学] 09[农学] 0906[农学-兽医学] 071007[理学-遗传学] 0901[农学-作物学] 0836[工学-生物工程] 090102[农学-作物遗传育种] 

主　　题：Hepatitis B virus Liver transplantation Recurrence Prophylaxis Hepatitis B immunoglobulin 

摘      要：Prophylactic strategies against hepatitis B virus(HBV) recurrence after liver transplantation(LT) are essential for patients with HBV-related *** LT, lamivudine(LAM) was proposed to be down-graded from first-to second-line *** contrast, adefovir dipivoxil(ADV) has been approved not only as first-line therapy but also as rescue therapy for patients with LAM ***, combination of ADV and LAM may result in lower risk of ADV resistance than ADV *** new drugs such as entecavir, telbivudine and tenofovir, are probably candidates for the treatment of hepatitis-B-surface-antigen-positive patients awaiting *** LT, low-dose intramuscular hepatitis B immunoglobulin(HBIG), in combination with LAM, has been regarded as the most cost-effective regimen for the prevention of post-transplant HBV recurrence in recipients without pretransplant LAM resistance and rapidly accepted in many transplant *** the introduction of new antiviral drugs, new hepatitis B vaccine and its new adjuvants, post-transplant HBIG-free therapeutic regimens with new oral antiviral drug combinations or active HBV vaccination combined with adjuvants will be promising, particularly in those patients with low risk of HBV recurrence.